Compare · ABT vs IRD
ABT vs IRD
Side-by-side comparison of Abbott Laboratories (ABT) and Opus Genetics Inc. (IRD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and IRD operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $158.63B, about 483.6x IRD ($328.0M).
- Over the past year, ABT is down 32.0% and IRD is up 281.8% - IRD leads by 313.9 points.
- IRD has been more active in the news (7 items in the past 4 weeks vs 6 for ABT).
- ABT has more recent analyst coverage (25 ratings vs 12 for IRD).
- Company
- Abbott Laboratories
- Opus Genetics Inc.
- Price
- $90.64-0.46%
- $3.99-1.48%
- Market cap
- $158.63B
- $328.0M
- 1M return
- +4.23%
- -25.49%
- 1Y return
- -32.04%
- +281.82%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 6
- 7
- Recent ratings
- 25
- 12
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- New research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workers
- New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis
- SEC Form SD filed by Abbott Laboratories
- Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes
- ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
- Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026
- SEC Form 4 filed by EXECUTIVE VICE PRESIDENT Moreland Mary K
- SEC Form SCHEDULE 13G filed by Abbott Laboratories
- SEC Form 10-Q filed by Abbott Laboratories
- Director Conroy Kevin T was granted 2,286 units of Common shares without par value, increasing direct ownership by 2% to 133,737 units (SEC Form 4)
Latest IRD
- SEC Form S-3 filed by Opus Genetics Inc.
- Guggenheim initiated coverage on Opus Genetics with a new price target
- Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts
- Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Opus Genetics to Present at the 2026 Jefferies Global Healthcare Conference
- Leerink Partners initiated coverage on Opus Genetics with a new price target
- Director Foundation Fighting Blindness Retinal Degeneration Fund sold $7,395,000 worth of shares (1,700,000 units at $4.35) (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Opus Genetics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Opus Genetics Inc.
- SEC Form S-8 filed by Opus Genetics Inc.